PMGC Holdings Inc（ELAB）資訊與事件ELABPMGC Holdings Inc

PMGC Terminates Letter of Intent to Acquire Arizona Company

PMGC announced that, following completion of audit-stage financial due diligence, it has terminated the previously announced non-binding letter of intent to acquire a 76% controlling interest in a privately held Arizona-based precision machining and contract manufacturing company. At the time of the announcement, PMGC stated that, based on unaudited financial information provided by the target, the business had generated approximately $5.46M in revenue and approximately $1.05M in EBITDA for fiscal year 2025. While PMGC continues to evaluate strategic acquisition opportunities, the company is also proactively investing in its existing aerospace and defense manufacturing businesses.

PMGC Enters Strategic Partnership with Orbit2Orbit

PMGC announced that it has entered into a non-binding term sheet with Orbit2Orbit outlining a proposed multi-part strategic relationship spanning space-based bioscience research, aerospace manufacturing, and a strategic investment by PMGC that would further expand the company's exposure to the growing commercial space economy. The proposed relationship is intended to combine capabilities across PMGC's operating businesses with Orbit2Orbit's spaceflight platform and its Mice2Space live-animal research capability, creating a differentiated framework to support biological research in microgravity while establishing a potential U.S.-based manufacturing relationship for future Orbit2Orbit space systems. Under the term sheet, the parties are contemplating three principal transactions. NorthStrive Biosciences, a wholly owned subsidiary of PMGC, and Orbit2Orbit intend to collaborate on the development and use of the Mice2Space live-animal research capability utilizing the Orbit2Orbit platform. NorthStrive Bio's study would evaluate its lead therapeutic candidates, EL-22 and EL-32, in mice for muscle retention and body composition outcomes in microgravity compared with Earth-based controls. The term sheet also contemplates A&B Aerospace serving as Orbit2Orbit's preferred U.S.-based manufacturing partner under a definitive agreement. As part of the proposed relationship, PMGC intends to subscribe for C$200,000 of Orbit2Orbit common shares at C$0.80 per share in connection with Orbit2Orbit's current private placement financing and proposed listing on the Canadian Securities Exchange through a reverse takeover transaction. The planned investment is intended to align PMGC with Orbit2Orbit's growth as the space technology company pursues its proposed public listing.

NorthStrive Files New Patents for Muscle Preservation

NorthStrive Biosciences announced the filing of two new U.S. patent applications directed to the use of its lead assets, EL-22 and EL-32, to preserve lean muscle mass in humans experiencing muscle loss caused by exposure to a microgravity environment. The applications have been assigned U.S. Patent Application Nos. 19/774,556 and 19/774,575. EL-22 is designed to target myostatin, and EL-32 to target both myostatin and activin A, proteins that negatively regulate skeletal muscle growth. The new filings apply that same biology, which NorthStrive is advancing for muscle preservation during glucagon-like peptide-1 receptor agonist and other obesity-related weight loss treatment, to a separate and clinically distinct patient population: humans whose skeletal muscle atrophies during spaceflight.